PureTech Health/$PRTC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About PureTech Health

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Ticker

$PRTC
Primary listing

Industry

Biotechnology

Employees

56

ISIN

US7462371060

PureTech Health Metrics

BasicAdvanced
$423M
85.43
$0.21
0.90
-

What the Analysts think about PureTech Health

Analyst ratings (Buy, Hold, Sell) for PureTech Health stock.

Bulls say / Bears say

PureTech Health's wholly owned program, deupirfenidone, achieved positive results in a Phase 2b trial for idiopathic pulmonary fibrosis, indicating strong potential for future approvals and market adoption. (marketbeat.com)
The FDA approval of KarXT, a treatment for schizophrenia invented at PureTech, marks a significant validation of the company's R&D capabilities and could lead to increased revenue streams. (investing.com)
Analysts at Leerink Partners initiated coverage on PureTech Health with an 'outperform' rating and a $45.00 price target, suggesting a potential upside of over 100% from the current stock price. (marketbeat.com)
PureTech Health reported a net loss of $66.6 million in 2023, raising concerns about the company's profitability and financial sustainability. (wikipedia.org)
The company's stock price has experienced significant volatility, with a 52-week low of $18.19, which may indicate investor uncertainty and potential downside risk. (investing.com)
Despite positive trial results, the competitive landscape in the biotechnology sector remains intense, potentially limiting PureTech's market share and revenue growth. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.

PureTech Health Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PureTech Health Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRTC

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs